Inhibikase Therapeutics (IKT) Equity Ratio (2020 - 2026)
Inhibikase Therapeutics (IKT) has 7 years of Equity Ratio data on record, last reported at 0.97 in Q1 2026.
- On a quarterly basis, Equity Ratio rose 6.35% to 0.97 in Q1 2026 year-over-year; TTM through Mar 2026 was 0.97, a 6.35% increase, with the full-year FY2025 number at 0.95, down 0.83% from a year prior.
- Equity Ratio reached 0.97 in Q1 2026 per IKT's latest filing, up from 0.95 in the prior quarter.
- Over the last five years, Equity Ratio for IKT hit a ceiling of 0.97 in Q1 2026 and a floor of 0.12 in Q3 2024.
- A 5-year average of 0.8 and a median of 0.88 in 2022 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: crashed 114.43% in 2024, then soared 855.51% in 2025.
- Tracing IKT's Equity Ratio over 5 years: stood at 0.84 in 2022, then dropped by 10.29% to 0.76 in 2023, then rose by 27.14% to 0.96 in 2024, then decreased by 0.83% to 0.95 in 2025, then rose by 1.35% to 0.97 in 2026.
- Business Quant data shows Equity Ratio for IKT at 0.97 in Q1 2026, 0.95 in Q4 2025, and 0.92 in Q3 2025.